ADMA Biologics, Inc.

Total Valuation

ADMA Biologics, Inc. carries a market capitalization of 2.23B, placing it among publicly traded companies globally. Its enterprise value stands at 1.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

ADMA Biologics, Inc. currently has 225.36M shares outstanding.

Valuation Ratios

ADMA Biologics, Inc. trades at a trailing price-to-earnings ratio of 11.65. The price-to-sales ratio is 3.84, and the price-to-book ratio stands at 4.62.

Enterprise Valuation

On an enterprise value basis, ADMA Biologics, Inc. trades at an EV/EBITDA multiple of 8.72 and an EV/FCF ratio of 11.91. The EV/Sales ratio of 3.81 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 9.03 provides insight into valuation relative to core operating earnings.

Financial Position

ADMA Biologics, Inc. maintains a current ratio of 6.97, meaning it holds 7.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 49.94, indicating elevated leverage, while an interest coverage ratio of 25.40 demonstrates strong ability to service its debt obligations.

Financial Efficiency

ADMA Biologics, Inc. posts a return on equity of 41.90 and a return on invested capital of 30.64.

Taxes

Over the trailing twelve months, ADMA Biologics, Inc. has paid 47.52M in income taxes, reflecting an effective tax rate of 21.95.

Stock Price Statistics

ADMA Biologics, Inc.'s stock has declined approximately -43.11059% over the past 52 weeks. The 50-day moving average sits at 9.13, while the 200-day moving average is 12.67.

Income Statement

Over the trailing twelve months, ADMA Biologics, Inc. generated 512.28M in revenue and converted that into 168.96M in net income, yielding earnings per share of 0.70. EBITDA reached 224.19M, while operating income came in at 216.50M.

Balance Sheet

ADMA Biologics, Inc. holds 136.02M in cash and equivalents against 203.84M in total debt, resulting in a net debt position of 60.57M. Total book value stands at 408.21M, with working capital of 452.45M providing operational flexibility.

Cash Flow

ADMA Biologics, Inc. produced 136.72M in operating cash flow over the past twelve months. After subtracting -20.50M in capital expenditures, free cash flow totaled 116.22M - equivalent to 0.49 per share.

Margins

ADMA Biologics, Inc. operates with a gross margin of 64.71, reflecting its pricing power and cost economics. The operating margin of 42.26 and net profit margin of 32.98 provide insight into operational efficiency.

Dividends & Yields

Scores

ADMA Biologics, Inc. posts an Altman Z-Score of 6.54, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.